Bradley Pharmaceuticals is hiring about 60 reps as it gears
up to launch Elestrin, a low-dose estrogen gel for treating the symptoms of
menopause.
The reps will pitch Elestrin to OB/GYNs as part of Bradley’s
Kenwood Therapeutics division, which received FDA approval for the product last
December.
The company estimates the size of the US estrogen therapy market, which
consists of oral and topical products, at $1.3 billion. The topical market is only
worth about $300 million.
Bradley in-licensed Elestrin from BioSante Pharmaceuticals late
last year and has the exclusive US
marketing rights.
The small specialty firm says Elestrin fits into its strategic
plan to in-license Phase II and Phase III drugs with long- term intellectual
property protection and bring them to market. Elestrin’s patent protects it
until 2022.